YourChoice
8 known investors
Find your way into YourChoice
Sign up to see every warm intro you have to YourChoice
- Paths you didn't know you had: your email and LinkedIn already hold routes to the YourChoice team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
YourChoice Therapeutics is developing YCT-529, a non-hormonal oral contraceptive for men currently in Phase 2 clinical trials. The company targets male contraceptive users seeking alternatives to condoms or vasectomy.
Founders & leadership

Investors · 8
How we know: Blue Bear Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Civilization Ventures Management, Llc's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Future Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Portfolia's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Related companies · 3
Companies working in the same space as YourChoice.
Frequently asked questions
- What does YourChoice do?
- YourChoice Therapeutics is developing YCT-529, a non-hormonal oral contraceptive for men currently in Phase 2 clinical trials. The company targets male contraceptive users seeking alternatives to condoms or vasectomy.
- Who founded YourChoice?
- YourChoice was founded by Akash Bakshi, MSc, Nadja Mannowetz, PhD.
- Who are YourChoice's investors?
- YourChoice's investors include Blue Bear Ventures, Civilization Ventures Management, Llc, Foreground Capital, Future Ventures, North South Ventures, Portfolia, Olive Tree Capital, Refactor Capital.




